Coronavirus: Hong Kong to Vaccinate 36,000 People Daily With Pfizer-BioNTech Jab

As Hong Kong prepares to administer the Covid-19 vaccine developed by BioNTech SE and Pfizer Inc. as early as the end of February, the city will set up 18 community vaccination centers -- one in every district -- to each handle at least 2,000 residents.

These centers will only handle the BioNTech vaccine, while the other two shots the city has ordered -- from Sinovac Biotech Ltd. and AstraZeneca Plc -- will be distributed to private hospitals and clinics, according to Thomas Tsang, a member of Hong Kong’s vaccination program task force.

The separate distribution is to avoid mixing up the vaccines, as the BioNTech shot needs to be handled at colder temperatures than the others. Hong Kong will allow people to choose their vaccine, though Sinovac and AstraZeneca’s shots won’t be available immediately since they haven’t cleared the city’s regulatory process.

The details come as Hong Kong adopts a “very careful” inoculation approach, opting for a smooth rollout rather than a speedy one to avoid any problems with supplies or possible surge in hospitalization.

“Our priority really is to have an organized program,” Tsang said in an interview Tuesday. “We try to do it as smoothly as possible, because that’s important to build public confidence. We surely don’t want something unexpected or some logistic hiccups.”

Unlike some pandemic hotspots such as London and New York, where governments are racing to inoculate their populations as quickly as possible to bring surging cases under control, Hong Kong can afford a more cautious pace. Its Covid-19 infections haven’t risen as drastically, with strict social-distancing rules keeping local cases to a few dozen daily.

Hong Kong won’t start jabbing its citizens until the end of February at the earliest. In an effort to prevent overburdening the city’s hospitals, Hong Kong may not vaccinate all elderly citizens and nursing homes at once, instead approaching such high-risk residents in stages.

“Once they’ve got fever, a lot of times they have to be admitted to hospital for observation,” said Tsang, former head of the Centre for Health Protection who got the nickname “superdetective” after leading a team to track the source of the SARS outbreak in the early 2000s. “We don’t want suddenly a surge of elderly home residents going to hospital.”

Hong Kong Chief Executive Carrie Lam on Tuesday said she has asked China to supply more inoculations because of a “hiccup” with the city’s other vaccine orders. An earlier report said Lam was seeking shots developed by Sinopharm, which currently doesn’t have a vaccine contract with Hong Kong.

The city has purchased enough doses of the Pfizer/BioNTech, Sinovac and Astra vaccines to cover its 7.5 million residents, and is looking for a fourth pact to boost coverage to twice its population.

Tsang said the BioNTech vaccines, which this week became the first to be approved by Hong Kong, will arrive in batches of 1 million to 1 1/2 million doses every month, though the first batch won’t arrive until the end of February. Shanghai Fosun Pharmaceutical Group Co., which is marketing the vaccine in the Greater China region, said Tuesday that the vaccines will be shipped directly from Germany and stored in low-temperature warehouses before being delivered to inoculation sites.

“We expect Sinovac to submit the complete clinical trial data with all the details included,” said Tsang. “Right now, we only have bits of pieces from officials in different places, but these are not up to our scientific standard. That’s a crucial bit of information that is missing -- and the same for AstraZeneca.”

The government hasn’t set a timeline for the rollout, Tsang said. But he hopes high-risk groups such as the elderly and health-care workers can be vaccinated within half a year or earlier.

“We need to roll it out first and see what happens before we come up with some concrete idea of what target are we going to make,” said Tsang. “Definitely, we’re in for a wild ride.”

Subscribe to our YouTube channel

Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.

To watch complete coverage on Bloomberg Quicktake 24/7, visit or watch on Apple TV, Roku, Samsung Smart TV, Fire TV and Android TV on the Bloomberg app.

Have a story to tell? Fill out this survey for a chance to have it featured on Bloomberg Quicktake

Connect with us on…

Breaking News on YouTube